Jim Hoffman: Persistent EBV Infection and the Promise of NET-Targeted Treatment
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Santersus AG’s post on LinkedIn:
” ‘Epstein-Barr virus (EBV) seropositivity is associated with chronic immune dysregulation conditions, including pediatric sepsis, multiple sclerosis, systemic lupus erythematosus, post–COVID-19 condition, and multiple cancers.’ Qin et al 2025
I am hopeful someone studying post-acute persistent EBV infection and reactivation that can result in autoreactive B cells, also known to upregulate PD-1 and ‘don’t eat me’ CD47 on certain cell types, will reach out to you to investigate your NET removal therapy.
EBV is also increasingly implicated in worsening cancer risk/progression.
I believe your NET removal therapy may very well reduce the severity of future EBV-related disease exacerbations that are thought to trigger/worsen the progression lupus and some cancers, with chronic ‘NETosis dysregulation’ as a very likely common link.
Your Nucleo Capture therapy, and perhaps DNase digestion, can both help boost innate phagocytic clearance of these resistant autoreactive B cell populations and infected EBV cells by depleting NETs and other extracellular chromatin.
Most importantly, can treating children with severe EBV infections reduce the risk of mortality from sepsis and delay or even reduce the risk of developing lupus and certain cancers in genetically predisposed infected individuals?”
Santersus AG shared a post on LinkedIn:
”Last spring, a teenage girl arrived in the ICU with severe lupus attacking her kidneys, heart, lungs, and brain at once. She was on a ventilator and despite maximal conventional therapy, her condition continued to worsen. Nucleo Capture was introduced as a rescue intervention.
Three sessions later, she was liberated from the ventilator and dialysis. By autumn, she had returned home and entered remission.
Her story is one of a growing number helping to shape the evidence base behind our pivotal program in severe, treatment-refractory systemic lupus erythematosus (SLE).
Today is World Lupus Day. Around 5 million people worldwide live with lupus. Many patients respond well to current therapies, but for others, disease activity persists despite escalating immunosuppression, leading to recurrent flares, progressive organ damage, and substantial treatment burden.
Nucleo Capture was designed for these patients. Rather than adding further systemic immunosuppression, our therapeutic apheresis platform selectively removes the upstream drivers of lupus inflammation: neutrophil extracellular traps (NETs) and cell-free DNA.
Nucleo Capture has received FDA Breakthrough Device Designation for severe, refractory SLE, and preparation for our pivotal trial in Europe is actively underway.
To every patient, family member, researcher, nurse and clinician continuing the fight against lupus: we’re with you.”
Title 1: Epstein-Barr Virus Seropositivity, Immune Dysregulation, and Mortality in Pediatric Sepsis
Authors: Aditya Sriram, Kate F. Kernan, Yidi Qin, Zachary Aldewereld, Andrew H. Walton, Stephanie Cabler, Gregory Storch, Valerie Cheynet, Karen Brengel-Pesce, Scott Canna, Joseph A. Carcillo, Robert A. Berg, Kathy L. Meert, Murray Pollack, Mark Hall, Kit Newth, Rick Harrison, Tom Shanley, Kenneth E. Remy, Hyun Jung Park
Title 2: Neutrophil Extracellular Traps: An Emerging Therapeutic Target to Improve Infectious Disease Outcomes
Authors: Angela Meier, George Sakoulas, Victor Nizet, Erlinda R. Ulloa
Stay updated on all scientific advances Hemostasis Today.
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis